Volker Schirrmacher

Volker Schirrmacher's AcademicInfluence.com Rankings

Volker Schirrmacher

Philosophy

#4813

World Rank

#7465

Historical Rank

Logic

#2192

World Rank

#3128

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Volker Schirrmacher Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Volker Schirrmacher's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) (2018) (481)
THE REQUIREMENT OF MORE THAN ONE ANTIGENIC DETERMINANT FOR IMMUNOGENICITY (1969) (396)
Bone marrow as a priming site for T-cell responses to blood-borne antigen (2003) (340)
Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. (1985) (300)
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow (2001) (290)
Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. (1983) (265)
Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin (1982) (222)
Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus. (1978) (203)
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. (2004) (202)
EGF receptor in neoplasia and metastasis (1993) (191)
Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis (2002) (174)
Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase (2009) (169)
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo (1979) (166)
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus (1999) (160)
Metastatic potential severely altered by changes in tumor cell adhesiveness and cell-surface sialylation (1983) (156)
Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients (2001) (155)
High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. (2005) (154)
Different patterns of lectin binding and cell surface sialylation detected on related high- and low-metastatic tumor lines. (1983) (154)
Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release. (1999) (150)
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. (1995) (147)
Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence (2006) (141)
Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. (2007) (140)
Further evidence for derepression of H–2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines (1976) (136)
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial (2008) (136)
Tumor Infiltrating T Lymphocytes in Colorectal Cancer: Tumor-Selective Activation and Cytotoxic Activity In Situ (2006) (132)
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. (2005) (131)
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory (2005) (127)
Heat-stable antigen (CD24) as ligand for mouse P-selectin. (1994) (126)
H–2-like specificities of foreign haplotypes appearing on a mouse sarcoma after vaccinia virus infection (1976) (122)
Effective subunit vaccines against an enveloped animal virus (1978) (121)
Induction of Interferon-α and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Human Blood Mononuclear Cells by Hemagglutinin-Neuraminidase but Not F Protein of Newcastle Disease Virus (2002) (116)
Co‐stimulatory effect of nitric oxide on endothelial NF‐κB implies a physiological self‐amplifying mechanism (1998) (116)
Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer (2008) (114)
Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. (2002) (111)
Immunization with virus-modified tumor cells. (1998) (111)
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes (1979) (110)
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects (1986) (109)
EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells. (1998) (109)
Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. (1994) (107)
TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus 1 (2003) (106)
Shifts in tumor cell phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis. (1980) (105)
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. (2004) (102)
Antitumor Vaccination in Patients with Head and Neck Squamous Cell Carcinomas with Autologous Virus-Modified Tumor Cells (2004) (101)
Proposed molecular basis of murine tumor cell-hepatocyte interaction. (1983) (101)
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy (2007) (100)
Anti-CD2 antibodies induce T cell unresponsiveness in vivo (1991) (92)
IMMUNE RESPONSES AGAINST NATIVE AND CHEMICALLY MODIFIED ALBUMINS IN MICE (1972) (92)
Suggestive evidence that the highly metastatic variant ESB of the T‐cell lymphoma eb is derived from spontaneous fusion with a host macrophage (1984) (92)
Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. (1998) (90)
Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody (1980) (88)
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. (2001) (88)
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. (2009) (87)
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. (1991) (86)
Induction of HLA class‐II antigen expression on human carcinoma cell lines by IFN‐gamma (1985) (84)
Nitric oxide-induced apoptosis in tumor cells. (2001) (79)
T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. (2003) (78)
p53 increases experimental metastatic capacity of murine carcinoma cells (1988) (74)
Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. (1990) (74)
Maintenance of long‐term tumour‐specific T‐cell memory by residual dormant tumour cells (2005) (72)
Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells (1985) (72)
Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. (1997) (72)
Newcastle disease virus activates macrophages for anti-tumor activity. (2000) (71)
Expression and function of the neural cell adhesion molecule L1 in mouse leukocytes (1992) (70)
Scattered micrometastases visualized at the single‐cell level: Detection and re‐isolation of lacZ‐labeled metastasized lymphoma cells (1994) (69)
Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. (2002) (69)
Superiority of the ear pinna over muscle tissue as site for DNA vaccination (1998) (69)
Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage (1984) (68)
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! (2016) (68)
Specific lymphocyte-activating determinants expressed on mouse macrophages (1975) (68)
Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. (2003) (68)
T-cell immunity in the induction and maintenance of a tumour dormant state. (2001) (66)
Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells (2000) (66)
Identification of asparagine-linked oligosaccharides involved in tumor cell adhesion to laminin and type IV collagen (1984) (66)
Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes (1981) (66)
The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. (2006) (64)
Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses (1993) (64)
Quantitative in vitro assay for tumor cell invasion through extracellular matrix or into protein gels. (1988) (64)
Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. (2009) (64)
ICE-proteases mediate HTLV-I Tax-induced apoptotic T-cell death (1997) (63)
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. (2008) (63)
High‐frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb) (1982) (62)
Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. (1998) (61)
Involvement of both heparanase and plasminogen activator in lymphoma cell‐mediated degradation of heparan sulfate in the subendothelial extracellular matrix (1986) (61)
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti‐tumor immunity in vivo and of cytolytic T cells in vitro (1979) (61)
In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. (1991) (60)
Qualitative differences in position of sialylation and surface expression of glycolipids between murine lymphomas with low metastatic (Eb) and high metastatic (ESb) potentials and isolation of a novel disialoganglioside (GD1 alpha) from Eb cells. (1986) (59)
Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. (1996) (59)
Dynamic Differentiation of Activated Human Peripheral Blood CD8+ and CD4+ Effector Memory T Cells (2005) (59)
Modification of tumor cells by a low dose of Newcastle Disease Virus. (1988) (59)
CD4+ helper T cells are required for resistance to a highly metastatic murine tumor (1987) (58)
Tumour cell–dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen‐glycol versus electro‐fusion protocols (2002) (58)
Purification and identification of chemokines potentially involved in kidney‐specific metastasis by a murine lymphoma variant: induction of migration and NFκB activation (1998) (57)
Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer (1997) (56)
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance (2015) (56)
Ligand mediated activation of ectopic EGF receptor promotes matrix protein adhesion and lung colonization of rat mammary adenocarcinoma cells. (1995) (56)
Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice (2007) (55)
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy (2019) (55)
Monoclonal antibodies which prevent experimental lung metastases (1984) (54)
Postoperative active specific immunization in colorectal cancer patients with virus‐modified autologous tumor‐cell vaccine. First clinical results with tumor‐cell vaccines modified with live but avirulent newcastle disease virus (1990) (54)
Interactions of Fc receptors with antibodies against Ia antigens and other cell surface components (1975) (53)
Sialoadhesin-positive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. (1999) (53)
Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant (1982) (52)
Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. (2003) (51)
Lymphoma cell interaction with cultured vascular endothelial cells and with the subendothelial basal lamina: attachment, invasion and morphological appearance. (1983) (51)
Cellular distribution and biological activity of epidermal growth factor receptors in A431 cells are influenced by cell‐cell contact (1990) (51)
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity (1980) (50)
Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. (1992) (50)
Liver endothelial cells participate in T‐cell‐dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo (1995) (50)
Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. (2004) (50)
Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice (2003) (50)
Characterization and isolation of a trypsin-like serine protease from a long-term culture cytolytic T cell line and its expression by functionally distinct T cells. (1986) (49)
Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants (2004) (49)
Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells. (2002) (49)
DETERMINATION OF ANTIBODY CLASS IN A SYSTEM OF COOPERATING ANTIGENIC DETERMINANTS (1970) (47)
The bacterial lacZ gene: An important tool for metastasis research and evaluation if new cancer therapies (1998) (47)
Antibody 12‐15 cross‐reacts with mouse Feγ receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein (1989) (46)
Characterization of cellular and extracellular plasma membrane vesicles from a non-metastasizing lymphoma (Eb) and its metastasizing variant (ESb). (1985) (46)
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study (2009) (46)
Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. (2006) (45)
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host (2013) (45)
Cognate interactions between memory T cells and tumor antigen‐presenting dendritic cells from bone marrow of breast cancer patients: Bidirectional cell stimulation, survival and antitumor activity in vivo (2003) (45)
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors (2004) (45)
Interferon production in the murine mixed lymphocyte culture. I. Interferon production caused by differences in the H‐2 K and H‐2 D region but not by differences in the I region or the M locus (1979) (44)
Prospects for cytokine and chemokine biotherapy. (1997) (44)
Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. (2002) (43)
Analysis of cell‐surface sugar receptor expression by neoglycoenzyme binding and adhesion to plastic‐immobilized neoglycoproteins for related weakly and strongly metastatic cell lines of murine tumor model systems (1990) (42)
Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b). (1995) (42)
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. (2007) (42)
A mouse hepatocyte carbohydrate‐specific receptor and its interaction with liver‐metastasizing tumor cells (1983) (42)
Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine (2000) (42)
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer (2013) (41)
A rapid method for the isolation of metastasizing tumour cells from internal organs with the help of isopycnic density-gradient centrifugation in Percoll. (1981) (41)
Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. (1995) (40)
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VII. Interaction of metastasizing and nonmetastasizing tumors with normal tissue in vitro. (1980) (39)
Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancer (1992) (39)
Glycoconjugates of murine tumor lines with different metastatic capacities. I. Differences in fucose utilization and in glycoprotein patterns (1984) (38)
Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. (2011) (38)
Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. (2006) (37)
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. (2011) (37)
DNA vaccination with asparaginyl endopeptidase (Sm32) from the parasite Schistosoma mansoni: anti-fecundity effect induced in mice. (2001) (37)
Changes in tumor cell adhesiveness affecting speed of dissemination and mode of metastatic growth. (1988) (37)
Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus. (1998) (36)
Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. (1997) (36)
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity (1987) (35)
Effective immune rejection of advanced metastasized cancer. (1995) (35)
Differential expression of endogenous sugar‐binding proteins (lectins) in murine tumor model systems with metastatic capacity (1987) (35)
STUDIES ON H‐2 SPECIFICITIES ON MOUSE TUMOUR CELLS BY A NEW MICRORADIOASSAY * (1977) (34)
Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. (1998) (34)
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. (2008) (34)
Plasmin in pericellular proteolysis and cellular invasion. (1994) (33)
Stimulation of human natural interferon-α response via paramyxovirus hemagglutinin lectin-cell interaction (2002) (33)
Evidence for a plasma membrane redox system on intact ascites tumor cells with different metastatic capacity. (1981) (33)
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function (2014) (33)
A NEW SENSITIVE ASSAY FOR ANTIBODY AGAINST CELL SURFACE ANTIGENS BASED ON INHIBITION OF CELL-DEPENDENT ANTIBODY-MEDIATED CYTOTOXICITY (1974) (33)
Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. (1990) (32)
A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes (2006) (32)
Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer (2008) (32)
Antigenic variation in cancer metastasis: immune escape versus immune control (2004) (32)
Cytogenetic changes during tumor progression towards invasion, metastasis and immune escape in the Eb/ESb model system (1982) (32)
Differences in the expression of histocompatibility antigens on mouse lymphocytes and tumor cells: immunochemical studies (1979) (32)
In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. (2006) (31)
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VIII. Expression and shedding of Fc gamma receptors on metastatic tumor cell variants. (1979) (31)
Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus (2005) (31)
Motility and invasive potency of murine T‐lymphoma cells: effect of microtubule inhibitors. (1994) (31)
Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients (2017) (31)
Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan (1988) (31)
Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity. (1989) (30)
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report (2014) (30)
Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism (2020) (30)
Immediate effects of reversible HTLV-ITax function: T-cell activation and apoptosis (1995) (29)
Modification of tumor cells by a low dose of Newcastle disease virus (2004) (29)
T Cell Memory, Anergy and Immunotherapy in Breast Cancer (2002) (29)
Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. (1997) (29)
Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. (2006) (29)
Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo (2007) (29)
CYTOTOXIC IMMUNE CELLS WITH SPECIFICITY FOR DEFINED SOLUBLE ANTIGENS (1974) (29)
Cytotoxic immune cells with specificity for defined soluble antigens. II. Chasing the killing cells. (1973) (28)
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 (2009) (28)
Skin-specific promoters for genetic immunisation by DNA electroporation. (2009) (28)
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report. (2015) (28)
Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. (1996) (28)
Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN‐α/β (1994) (27)
Tumour‐Specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens (1993) (27)
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis (2020) (27)
Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review). (2015) (27)
Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications (2021) (27)
Effect of thymus factor on human precursor T lymphocytes (1975) (27)
Induction of CD44 expression by the epstein‐barr virus latent membrane protein LMP1 is associated with lymphoma dissemination (1995) (27)
Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity. (2011) (26)
Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H‐2 identical immune T cells from B10.D2 mice (1979) (26)
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. (2005) (26)
Active Specific Immunotherapy with Autologous Tumor Cell Vaccines Modified by Newcastle Disease Virus: Experimental and Clinical Studies (1989) (26)
Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma. (1994) (26)
Activated endothelial cells induce apoptosis in lymphoma cells. (1997) (26)
Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. (1992) (25)
Expression of epidermal growth-factor receptor correlates with metastatic potential of 13762nf rat mammary adenocarcinoma cells. (1994) (25)
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. (2005) (25)
Possible cell surface receptor for Friend murine leukemia virus isolated with viral envelope glycoprotein complexes (1980) (25)
Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages. (1998) (25)
Structural basis for altered soybean agglutinin lectin binding between a murine metastatic lymphoma and an adhesive low malignant variant. (1987) (25)
Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. (2012) (24)
Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. (1998) (24)
Dynamic expression changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastasis. (1996) (24)
Characterization of an extracellular matrix-degrading protease derived from a highly metastatic tumor cell line. (1985) (23)
Redox events in HTLV-1 Tax-induced apoptotic T-cell death. (2002) (23)
An analysis of autologous T‐cell anti‐tumour responses in colon‐carcinoma patients following active specific immunization (ASI) (1992) (23)
Targeting anti-tumor DNA vaccines to dendritic cells via a short CD11c promoter sequence. (2009) (23)
Expression of L1 cell adhesion molecule is associated with lymphoma growth and metastasis (1993) (23)
Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. (1988) (23)
Tumor cell vaccination for gynecological tumors. (1993) (22)
Nucleocytoplasmic transport of HTLV-1 RNA is regulated by two independent LTR encoded nuclear retention elements (1998) (22)
Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. (2005) (22)
Tumor‐specific T‐cell clones recognize different protein determinants of autologous human malignant melanoma cells (1990) (22)
The extended packaging sequence of MoMLV contains a constitutive mRNA nuclear export function (1998) (22)
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged (2020) (21)
Characteristics of alloantigens and cellular mechanisms responsible for gamma-interferon production in primary murine MLC. (1981) (21)
High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. (2004) (21)
Rapid effects of EGF on cytoskeletal structures and adhesive properties of highly metastatic rat mammary adenocarcinoma cells (2004) (21)
A new sensitive assay for antibody against cell surface antigens based on inhibition of cell-dependent antibody-mediated cutotoxicity. II. Mechanism. (1975) (21)
Ligand-induced activation of epidermal growth factor receptor in intact rat mammary adenocarcinoma cells without detectable receptor phosphorylation. (1992) (21)
Association of CD2 and T200 (CD45) in mouse T lymphocytes. (1990) (21)
Pattern and load of spontaneous liver metastasis dependent on host immune status studied with a lacZ transduced lymphoma (1994) (20)
Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. (2009) (20)
New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. (1987) (20)
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. (2009) (20)
New insights into tumor-host interactions in lymphoma metastasis (1996) (20)
Inheritance of immunogenicity and metastatic potential in murine cell hybrids from the T-lymphoma ESb08 and normal spleen lymphocytes. (1984) (20)
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. (2008) (19)
Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. (2005) (19)
A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo. (1996) (19)
Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine (2005) (19)
In-situ activated macrophages are involved in host-resistance to lymphoma metastasis by production of nitric-oxide. (1995) (18)
In Vivo 1H‐NMR microimaging with respiratory triggering for monitoring adoptive immunotherapy of metastatic mouse lymphoma (1997) (18)
Activation of platelet heparitinase by tumor cell-derived factors. (1991) (18)
Expression of Ia antigens in a murine T-lymphoma variant. (1985) (18)
Studies on interleukin 2 receptor expression and IL-2 production by murine T cell lymphomas. (1985) (18)
Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures. (1999) (18)
Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. II. Influence of minor histocompatibility antigens on tumor resistance, gamma-interferon induction and cytotoxic response. (1981) (18)
Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity. (2000) (18)
Loss of endogenous mouse mammary tumor virus superantigen increases tumor resistance. (1998) (17)
Cancer Immunotherapy: Battling Tumors with Gene Vaccines (2005) (17)
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. (2010) (17)
Inhibition of nitric-oxide-mediated apoptosis in Jurkat leukemia cells despite cytochrome c release. (2001) (17)
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. (1989) (17)
Antibody targeting to the murine lymphoma ESb‐MP: Increased accumulation due to reduced internauzation into lymphoma cells as compared to normal lymphoid cells (1988) (16)
Syngeneic tumor cells can induce alloreactive T killer cells: a biological role for transplantation antigens. (1980) (16)
Tumor immunology: Paul Ehrlich's heritage. (1989) (16)
Integration of a virus membrane protein intothe lipid bilayer of target cells as a prerequisite for immune cytolysis. Specific cytolysis after virosome- target cell fusion (1979) (16)
Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. (1976) (16)
Gene transfer and genetic modification of embryonic stem cells by Cre‐ and Cre‐PR‐expressing MESV‐based retroviral vectors (2004) (16)
Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study. (2015) (16)
Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. (2011) (16)
Growth and metastasis of human tumors in nude mice following tumor‐cell inoculation into a vascularized polyurethane sponge matrix (1988) (15)
ACTIVATED T LYMPHOCYTES EXPRESS NEW SURFACE DETERMINANTS WHICH REACT WITH HETEROLOGOUS ANTI‐B CELL SERUM (1975) (15)
Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity. (2011) (15)
The activation domain of a hormone inducible HTLV-1 Rex protein determines colocalization with the nuclear pore. (1997) (15)
Tumour targeting with antibody-coupled liposomes: Failure to achieve accumulation in xenografts and spontaneous liver metastases (1990) (15)
The immune response against hapten-autologous protein conjugates in the mouse. IV. Thymus dependency of the primary response to hapten-autologous albumin conjugates. (1973) (15)
Recruitment and activation of tumor‐specific immune t cells in situ: Functional studies using a sponge matrix model (1989) (14)
Gamma-irradiation suppresses T-cell mediated protective immunity against a metastatic tumor in the afferent phase of the immune-response but enhances it in the efferent phase when given before immune cell transfer. (1994) (14)
Cytotoxic immune cells with specificity for defined soluble antigens. V. Interaction of antibody with the cytotoxic effector cells in immune or non-immune mouse spleen cells. (1974) (14)
Tumor vaccine design: concepts, mechanisms, and efficacy testing. (1995) (14)
Characterization of cellular and extracellular plasma membrane vesicles from a low metastatic lymphoma (Eb) and its high metastatic variant (ESb): inhibitory capacity in cell-cell interaction systems. (1986) (14)
Immunoresistant metastatic tumor variants can re‐express their tumor antigen after treatment with DNA methylation‐inhibiting agents (1986) (14)
Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies (2014) (13)
Adhesive function of newcastle-disease virus hemagglutinin in tumor-host interaction. (1995) (13)
In vitro Studies on Tumor Cell Interaction with the Vascular Endothelium and the Subendothelial Basal Lamina: Relationship to Tumor Cell Metastasis (1983) (13)
Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies (1996) (13)
Cytotoxic immune cells with specificity for defined soluble antigens. I. Assay with antigen-coated target cells. (1973) (13)
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience (2020) (13)
Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow (2001) (13)
Effects of mutagens on the immunogenicity of murine tumor cells: immunological and biochemical evidence for altered cell surface antigens. (1985) (13)
T cell-mediated immunotherapy of metastases: state of the art in 2005 (2005) (13)
Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer (2008) (13)
Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity (2014) (12)
Cancer-reactive memory T cells from bone marrow: Spontaneous induction and therapeutic potential (Review). (2015) (12)
Superiority of the ear pinna over a subcutaneous tumour inoculation site for induction of a Th1-type cytokine response (1998) (12)
Breaking tolerance to a tumor‐associated viral superantigen as a basis for graft‐versus‐leukemia reactivity (2000) (12)
Cytotoxic immune cells with specificity for defined soluble antigens. 3. Separation from helper cells and from antibody-forming cell precursors. (1973) (12)
Murine Fcγ receptor proteins: identification of a previously unrecognized molecule with a monoclonal antibody (12‐15) (1988) (11)
Characterization of a murine lymphoma cell line by 31P‐NMR spectroscopy: In vivo monitoring of the local anti‐tumor effects of systemic immune cell transfer (1996) (11)
Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity. (1987) (11)
TPA-Induced Modulation of B Cell Differentiation Antigens Defined by Monoclonal Antibodies (HD6, HD28, HD37, HD39) (1986) (11)
Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkappaB activation. (1998) (11)
New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection (2020) (11)
Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity. (1998) (11)
Quantitative determination of disseminated tumor cells by [3H]thymidine incorporation in vitro and by agar colony formation. (1982) (10)
Fibrin autography of plasminogen activator by electrophoretic transfer into fibrin agar gels. (1988) (10)
Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing (1989) (10)
A novel tumour model system for the study of long-term protective immunity and immune T cell memory. (2003) (10)
Characteristics of a potent tumor vaccine-induced secondary anti-tumor T cell response. (2004) (10)
A T-cell-related proteinase expressed by T-lymphoma cells activates their endogenous pro-urokinase. (1992) (10)
[Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization]. (1995) (10)
Quantitative analysis of cancer invasion in vitro: comparison of two new assays and of tumour sublines with different metastatic capacity (1986) (9)
Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25. (2010) (9)
Foreign H-2-like molecules on a murine tumor (MCG4): target antigens for alloreactive cytolytic T lymphocytes (CTL) and restricting elements for virus-specific CTL. (1980) (9)
A model to account for the effects of oncogenes, TPA, and retinoic acid on the regulation of genes involved in metastasis (1988) (9)
Expression and enhanced secretion of proteochondroitin sulphate in a metastatic variant of a mouse lymphoma cell line. (1988) (9)
New plasma membrane proteins expressed by a high metastatic variant of a chemically induced tumor. (1984) (9)
Enrichment of functional CD8 memory T cells specific for MUC1 in Bone Marrow of Multiple Myeloma Patients (2004) (9)
Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals (2014) (9)
Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus. (2004) (9)
Matrix heparan sulphate, but not endothelial cell surface heparan sulphate, is degraded by highly metastatic mouse lymphoma cells. (1988) (9)
Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status : A study in ex vivo-isolated endothelial cells (1998) (9)
A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. (1979) (8)
Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status--a study in ex vivo-isolated endothelial cells. (1998) (8)
Genetic separation of GvL and GvH reactivity in new recombinant-inbred tumor-resistant mouse strains. (1996) (8)
The synthesis of radioactively labeled sulfanyl‐N‐chloracetyl tyrosine and its use for determinations of quantities and affinities of anti‐p‐azobenzenesulfonate antibodies (1972) (8)
Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model. (1989) (8)
The Immune Response against Hapten‐Autologous Protein Conjugates in the Mouse (1973) (8)
Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants. I. Effect of incompatibilities at H-2 or non-H-2 genes in normal and nude (nu/nu) mice. (1981) (8)
Analysis of metastatic competence of mouse bladder carcinoma cells after transfection with activated Ha-ras or N-ras oncogenes (1988) (8)
Changes in liver glycogen and lipid metabolism during transient graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivity. (1996) (7)
Spontaneous Phenotypic Shifts from Low to High Metastatic Capacity (1983) (7)
Affinity fractionation of lymphoid cells according to type and function. (1972) (7)
Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus (2022) (7)
A RADIOASSAY FOR MACROPHAGES AND ITS APPLICATION FOR TESTING MACROPHAGE MEMBRANE ANTIGENS (1975) (7)
Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. 2. Characteristics of a metastasizing variant of a chemically induced lymphoma. (1979) (7)
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines (2005) (7)
Danger signals in tumor cells: a risk factor for autoimmune disease? (2010) (7)
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients (2022) (7)
In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: Intra-pinna immunization followed by restimulation in the peritoneal cavity (2005) (7)
Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase. (1992) (7)
EXPRESSION OF FOREIGN H‐2‐LIKE ANTIGENS BY A CHEMICALLY‐INDUCED MURINE TUMOUR (MCG4) (1980) (7)
An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules (1999) (7)
Tumours of the spine (2012) (7)
Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: Migration, survival and tumor-protectivity of cytotoxic donor cells (1991) (7)
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counteracting Treg activity (2011) (6)
Novel adenomatous polyposis coli gene promoter is located 40 kb upstream of the initiating methionine. (2005) (6)
Clonal analysis of H-2 antigen expression by variants of a chemically induced murine tumor. (1981) (6)
Alloantibody production by nude mice. (1980) (6)
Mechanisms of metastatic spread to liver. (1986) (6)
Newcastle Disease Virus: A Promising Vector for Viral Therapy of Cancer (2008) (6)
Metastatic tumor cell variants with increased resistance to infection by Semliki Forest virus. (1981) (6)
Active Specific Immunotherapy – A New Modality of Cancer Treatment Involving the Patient’s Own Immune System (1993) (6)
Induction of anti-hapten antibody responses against haptens conjugated to autologous and heterologous proteins. (1973) (6)
Intra-pinna induction of specific antitumor immune T cell functions. (1997) (6)
Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. (2010) (6)
Superantigen reactive Vβ6+ T cells induce perforin/granzyme B mediated caspase-independent apoptosis in tumour cells (2002) (6)
Biotherapy of cancer. Perspectives of immunotherapy and gene therapy. (1995) (6)
Ear Pinna : a privileged DNA electroporation site for inducing strong Th1 immune responses (2009) (5)
Peripheral immunization against malignant rat glioma can induce effective antitumor immunity in the brain. (1995) (5)
Effect of thymic factor on human lymphoid cells of umbilical cord blood and of children with T cell deficiency. (1977) (5)
Phenotypic and genotypic differences between high- and low-metastatic related tumor lines and the problem of tumor progression and variant generation. (1983) (5)
This information is current as Memory T Cells Effector + and CD 4 + Peripheral Blood CD 8 Dynamic Differentiation of Activated Human and (2005) (5)
In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination. (1999) (5)
Tumor-immune memory T cells from the bone marrow exert GvL without GvH reactivity in advanced metastasized cancer. (2005) (5)
Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum (2004) (5)
Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene (2004) (5)
[Adjuvant therapy of liver metastases: active specific immunotherapy]. (1995) (5)
Clonal analysis of expression of tumor-associated transplantation antigens and of metastatic capacity (2004) (5)
Immunotherapy of metastases. (1996) (5)
H-2 histocompatibility antigens of subcellular membranes of mouse liver. (1979) (4)
Change in organotropism of mouse lymphoma variants associated with selective chemotactic responsiveness to organ-derived chemoattractants (1991) (4)
A NEW S ENSITIVE ASSAY FOR ANTIBODY AGAINST CELL SURFACE ANTIGENS BASED ON INHIBITION OF CELL-DEPENDENT A NTIBODY-MEDIATE D CYTOTOXICITY I. Specificity and Sensitivity* (1974) (4)
Fc receptors and Ia antigens. (1976) (4)
Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. (1998) (4)
Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta. (1993) (4)
Local Tumor Growth and Spontaneous Systemic T Cell Responses in Cancer Patients: A Paradox and Puzzle (2008) (4)
Characterization of antigens on murine tumor cells reacting with alloantisera against foreign H-2 specificities: analysis by absorption with purified murine leukemia virus and normal lymphoid cells of different H-2 haplotypes. (1978) (4)
Liver endothelial cells: participation in host response to lymphoma metastasis (1996) (4)
Expression of RIGI , IRF 3 , IFN-ß and IRF 7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus (4)
A fast-acting cytotoxin derived from Con A-activated porcine leukocytes. I. Biochemical characteristics and target cell specificity. (1986) (4)
Species-restricted antibody response against a DNA-construct coding for aspartic proteinase from Schistosoma japonicum (2002) (4)
Antibodies induced in mice by a DNA-construct coding for the elastase of Schistosoma mansoni recognize the enzyme in secretions and preacetabular glands of cercariae (2002) (4)
Adoptive transfer of protective immunity against a high metastatic tumor-cell variant by small numbers of tumor-specific in-situ activated peritoneal effector T-cells. (1994) (4)
Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine (2011) (4)
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit (2020) (4)
Effects of RA 233 treatment on the adhesive, invasive and metastatic properties of 13762NF rat mammary tumor cells (1989) (3)
4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon-alpha2b (1995) (3)
Antitumor Immune Memory And Its Activation For Control Of Residual Tumor Cells And Improvement Of Patient Survival: A New Concept Derived From Translational Research With The Virusmodified Tumor Vaccine Atv-Ndv (2004) (3)
Regulation of plasminogen-activator in mastocytoma cells by lymphokines. (1983) (3)
The relationship between alloantigen responses in nude mice injected with a low number of congenic thymus cells. (1980) (3)
Biotechnological production and functional characterization of leukocytic cytokine(s) with cytotoxic effect on resting but not activated thymocytes. (1985) (3)
In situ downregulation of VLA-4 integrin cell surface expression during lymphoma growth and liver metastasis. (1997) (3)
Mechanism of Transendothelial Cell Passage and Matrix Degradation by Metastatic Tumor Cells (1987) (3)
A radioassay for the study of cell surface determinants on activated lymphocytes. (1975) (3)
Preferential antibody targeting to small lymphoma metastases in the absence of the primary tumour. (1993) (3)
In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells (1993) (3)
Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages:in vitro analysis of tumor cell binding and cytostasis (2005) (3)
TUMOR METASTASES AND CELL-MEDIATED IMMUNITY IN A MODEL SYSTEM IN DBA/2 MICE 3. INDUCTION AND SPECIFICITY OF SYNGENEIC CYTOTOXIC T CELLS (1979) (3)
THE EXPRESSION OF H‐2K, H‐2D AND Ia ANTIGENS IN VARIOUS TISSUES AS ASSESSED IN Fc RECEPTOR INHIBITION SYSTEMS (1975) (3)
Virus spike protein complexes and virosomes as effective subunit vaccines. (1979) (3)
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer (2012) (3)
Augmentation of protective immunotherapy against metastatic esb lymphoma-cells by combining immune cell transfer with host irradiation, antigen restimulation and/or anti-tnf-alpha antibody treatment. (1995) (3)
Unexpected H-2 antigen expression by mouse tumor cells, a cautionary note (2004) (2)
Studies on the expression of cell surface determinants on activated mouse lymphocytes (1976) (2)
IN VITRO INVASION OF LYMPHOMAS WITH DIFFERENT METASTATIC CAPACITY (1982) (2)
14C-thymidine release assay: a new test for the study of surface determinants on activated lymphocytes. (2008) (2)
Adoptive transfer via immune T-lymphocytes of effective anti-tumor immunity against a malignant rat glioma in the brain. (1997) (2)
Generation of adhesive tumor variants: Chromosomal changes, reduction in malignancy and increased expression of a distinct membrane glycoprotein (1988) (2)
[Tumor cell immunogenicity and T-cell-mediated antitumor immune reactions. Modulation and application to immunotherapy]. (1987) (2)
Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo. (1999) (2)
EXPRESSION OF H-2 SPECIFICITIES AND OF MuLV ENVELOPE ANTIGENS ON MURINE TUMORS (1977) (2)
Heterogeneity of glycoprotein synthesis in human tumor cell lines. (1986) (2)
Cancer metastasis and the use of animal model systems. (1984) (2)
Clonal Tumor Cell Variants Arising by Adaptation (1980) (2)
Molecular identification of lectin binding sites differentiating related low and high metastatic murine lymphomas (2005) (2)
Murine lymphoma cells possess blood group Tn-, T-, N-, M- and S-active substances (1983) (2)
Dendritic Cells Pulsed with Viral Oncolysate (2013) (2)
ATIM-30. HOW TO MONITOR IMMUNOGENIC CELL DEATH IN PATIENTS WITH GLIOBLASTOMA (2018) (2)
Quo vadis cancer therapy (2017) (2)
[Anti-tumor vaccination]. (2000) (2)
Quantitation of antibody uptake in spontaneous metastases. (1990) (2)
[Invasive, metastatic growth of lymphoblastoid B cells in immunodeficient SCID mice]. (1991) (2)
Position paper: new insights into the immunobiology and dynamics of tumor–host interactions require adaptations of clinical studies (2020) (2)
Oncogene expression in related cancer lines differing in metastatic capacity (1988) (2)
Cancer metastasis : molecular and cellular biology, host, immune response, and perspectives for treatment (1989) (2)
T cell based immunotherapy – Changes and challenges (2006) (1)
Dissection of tumor and host cells from metastasized organs for testing gene expression directly ex vivo. (2001) (1)
Transforming growth factor-beta production and induction of cellular responses in 13762NF rat mammary adenocarcinoma cell clones. (1993) (1)
DIPG-10. MULTIMODAL IMMUNOTHERAPY AS PART OF MULTIMODAL TREATMENT FOR DIPG (2017) (1)
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells derived from bone marrow (2005) (1)
Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon α2b (1991) (1)
Virus modified tumor cell vaccines for active specific immunotherapy of micrometastases: expansion and activation of tumor-specific T cells. (1989) (1)
Immune responses against native and chemically modified albumins in mice. II. Effect of electric charge and conformation on the humoral antibody response and on helper T cell responses. (1974) (1)
Dissection of tumour and host cells from target organs of metastasis for testing gene expression directly ex vivo. (1996) (1)
Assay for the determination of human carcinoma cells in circulating blood (2004) (1)
Induction of the metastatic phenotype by transfection of the nuclear oncogene p53: Increases in cytoplasmic diacylglycerol levels and reduction in class I major histocompatibility antigen expression are not sufficient to explain the changes in metastatic capacities (2004) (1)
The specificity and significance of the inhibition of Fc receptor binding by anti H-2 sera (1975) (1)
Protective Immunity against Metastasis: Basic Studies and Clinical Application (1992) (1)
Biotherapy of cancer (1995) (1)
Scientific Proceedings Fifth Symposium of the Section of Experimental Cancer Research (SEK) of the German Cancer Society (2004) (1)
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM) (2004) (1)
A fast-acting cytotoxin derived from Con A-activated porcine leukocytes. II. Mechanism of target cell lysis. (1986) (1)
Workshop: Active Specific Immunotherapy with Tumor Cell Vaccines (2005) (1)
Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice (2005) (1)
Changes in metastasis formation and distinct cell surface molecules in adhesion variants of a metastatic murine tumor. (1988) (1)
Generation of Stable Antigen Loss Variants from Cloned Tumor Lines—An Example of Immunoadaptation During Metastasis (1981) (1)
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy (2022) (1)
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous Memory T-cells (MTC) derived from bone marrow (BM). (2004) (1)
Successful Application of a Virus-Modified Tumor Vaccine for Anti-Metastatic Cancer Immunotherapy (1989) (1)
Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007 (2008) (1)
IMMU-07. IMMUNOGENIC CELL DEATH DURING MAINTENANCE CHEMOTHERAPY AND SUBSEQUENT MULTIMODAL IMMUNOTHERAPY FOR GBM (2018) (1)
CELL SURFACE DETERMINANTS—NEW METHODS OF DETECTION AND BIOLOGICAL IMPLICATIONS: A GENERAL SURVEY (1975) (1)
Time for cancer Immunotherapy (2018) (1)
In Vitro Interactions of Aortic Endothelial Cell Monolayers with Tumor Cell Lines of Different Invasive and Metastatic Capacity (1983) (1)
A Role for Cell Surface Sialic Acid in Liberating Metastatic Tumor Cells from Host Control (1986) (1)
Foreign H-2-like ,olecules on a murine tumor (MCG4) (1980) (0)
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience (2023) (0)
[Immunotherapy of hemato-oncologic diseases]. (1996) (0)
Human T Cell Leukemia Virus-I ( HTLV-I ) Tax-Mediated Apoptosis in Activated T Cells Requires an Enhanced Intracellular Prooxidant State 1 (1998) (0)
Bispecific antibody modified tumor veaccine for human T cell stimulation (1997) (0)
Requires an Enhanced Intracellular Tax-Mediated Apoptosis in Activated T Cells Human T Cell Leukemia Virus-I (HTLV-I) (2013) (0)
HGG-05. CAN MULTIMODAL IMMUNOTHERAPY REPLACE RADIOCHEMOTHERAPY IN COMPLETELY RESECTED ADULT GBM? (2017) (0)
Multimodal immunotherapy for DIPG: status today (2016) (0)
Activation of Tumor‐Specific CTLP to a Cytolytic Stage Requires Additional Signals (1988) (0)
Different H-2 antigens expressed on two tumors derived from one BALB/c mouse. (1981) (0)
Subject Index Vol. 108, 1995 (1995) (0)
Cell Biology of Tumor Metastasis Formation (1989) (0)
Effective introduction of T cell costimulatory molecules into virus modified tumor cell vaccines by modification with bispecific antibodies. (1997) (0)
Models for Immunotherapy and Cancer Vaccines (2005) (0)
Functional tumor reactive T cells in bone marrow and blood of pancreatic cancer patients (2005) (0)
Tumor epitope detection in monocytes (EDIM) as a marker for antitumoral activity of Newcastle disease virus infusion and modulated electrohyperthermia (2018) (0)
Effects of adjuvant therapies in breast cancer on tumor specific memory T cells (MTC) derived from bone marrow (bm) (2003) (0)
DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN (2020) (0)
Virus Superantigen Increases Tumor Resistance Loss of Endogenous Mouse Mammary Tumor (1998) (0)
Treatment of Patients with Advanced Renal Cell Carcinoma with Autologous Tumor Vaccine and Subcutaneous Administration of Recombinant Interleukin-2 and Interferon-alpha2b, Survival Data (1995) (0)
Postoperative activation of tumor specific T cells by immunization with virus-modified tumor cells and effects on metastasis. (1988) (0)
Studies on the specificity of cooperating thymus derived cells (1972) (0)
O-81 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patient (2007) (0)
Current Cancer Research 1986 (1986) (0)
7th International Symposium of the Division of Experimental Cancer Research (AEK) of the German Cancer Society (1994) (0)
Modulations of tumor cell immunogenicity resulting in increase of t cell reactivity (1985) (0)
Cell surface glycoprotein differences between a highly malignant murine tumor line and a plastic-adherent, less malignant variant. (1987) (0)
P102 Cellular immunotherapy in late stage breast cancerpatients with reactivated autologous Memory T-cells derived from bone marrow (2005) (0)
II. International Congress of the Metastasis Research Society, Heidelberg, 26–29 September 1988 (1989) (0)
Cytotoxin with anti tumor activity produced by porcine peripheral blood leukocytes studies on its specificity mode of action and physical properties (1985) (0)
Clinical perspectives for the treatment of metastases (1989) (0)
Experimental Basis for Immunotherapy of Metastases (1998) (0)
[Effect of imidazole derivatives and other 5-membered heterocyclic compounds on adenine phosphoribosyltransferase]. (1967) (0)
Immunological effects after an adoptive cellular immunotherapy with reactivated autologous memory T-Cells from bone marrow. (2006) (0)
Change in metastasis and organotropism of mouse lymphoma variants associated with changes in expression of adhesion molecules and chemotactic responsiveness (1991) (0)
IMMU-25. SYNERGY BETWEEN TMZ AND INDIVIDUALIZED MULTIMODAL IMMUNOTHERAPY TO IMPROVE OS OF IDH1 WILD TYPE MGMT PROMOTOR UNMETHYLATED GBM PATIENTS (2021) (0)
Immunological aspects in oncology (1989) (0)
Dissection oftumourandhostcells fromtarget organsofmetastasis for testing geneexpression directly ex vivo (1996) (0)
Superantigen recognition facilitating graft versus leukemia reactivity leading to complete remissions (1998) (0)
Evolution of the Leukemic State Group Report (1985) (0)
P15 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patients (2007) (0)
Interactions of breast cancer cells and tumorantigen-reactive T-cells derived from bone marrow (2007) (0)
Late abstracts 186–187 (2005) (0)
Cytologic and flow cytometric DNA analysis of multinucleated tumor cells and derived microcells. (1989) (0)
[Cell biology principles of metastasis and strategies for immunotherapy]. (1989) (0)
Improvement of Anti-Tumor DNA Vaccination by Co-Immunization at a Distant Site with a Plasmid Encoding the Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus (2010) (0)
Sulfated glycosaminoglycans accelerate the activation of PRO-uPA and plasminogen and stimulate in vitro invasion of tumor cells (1989) (0)
Modulated electrohyperthermia as part of immunogenic cell death treatment in pediatric neuro-oncology (2019) (0)
Differences in glycosidase spectrum between related tumor cell lines (1985) (0)
VirusMonocytes Stimulated by Newcastle Disease Mediates Tumoricidal Activity of Human TNF-Related Apoptosis-Inducing Ligand (2003) (0)
The Immun System, F. Melchers, K. Rajewsky (Eds.). Springer-Verlag, Berlin • Heidelberg • New York (1976), 104 figs., XII, 299 pages (27. Kolloquium, Ges. für Biol. Chemie 29. 4.-1. 5. 1976 in Mosbach). US-$ 21.70 (1979) (0)
Interaction of Metastatic and Non-Metastatic Tumor Lines with Aortic Endothelial Cell Monolayer and Their Underlying Basal Lamina (1983) (0)
Combined Vaccination with Autologous Tumor Material and Subcutaneously Administered rIL-2 and rIFN-α-2b in the Treatment of Renal Cell Carcinoma (1992) (0)
Individualized Multimodal Immunotherapy for DIPG: Part of the Game (2021) (0)
New Experimental Approaches to the Therapy of Metastasis in Tumor Model Systems (1988) (0)
HG-21NEXT GENERATION IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA. (2016) (0)
Contents, Vol. 108, 1995 (1995) (0)
Cell adhesion and migration of different human colon cell lines and primary tumors (2004) (0)
immune status studied with a lacZ transduced lymphoma Pattern and load of spontaneous liver metastasis dependent on host (2011) (0)
Multimodal immunotherapy integrated into standard therapy for GBM: learning from clinical practice (2018) (0)
[Tumor vaccines and active specific immunotherapy]. (1997) (0)
Isolated Endothelial Cells - A Study in Ex Vivo -- Affected by Tumor Cells and Host Immune Status Identification of Four Genes in Endothelial Cells Whose Expression Is (2013) (0)
Prevention of postoperative metastic spread (1985) (0)
Antibody-dependent cell-mediated cytotoxicity in the mouse. I. Surface characteristics of an effecter cell. (1974) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Volker Schirrmacher?

Volker Schirrmacher is affiliated with the following schools:

Volker Schirrmacher's Academic­Influence.com Rankings

Why Is Volker Schirrmacher Influential?

Volker Schirrmacher's Published Works

Published Works

What Schools Are Affiliated With Volker Schirrmacher?

Volker Schirrmacher's AcademicInfluence.com Rankings